Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management
Diabetologia · 2024-12 · 67 (12) · 2611-2625
DOI: 10.1007/s00125-024-06242-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetologia, online erschienen am 09.08.2024. Verfasst von Aikaterini Eleftheriadou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Diabetic Neuropathies, Cardiovascular Diseases. Die Arbeit wurde bisher 95-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Cardiovascular autonomic neuropathy (CAN) is an under-recognised yet highly prevalent microvascular complication of diabetes. CAN affects approximately 20% of people with diabetes, with recent studies highlighting the presence of CAN in prediabetes (impaired glucose tolerance and/or impaired fasting glucose), indicating early involvement of the autonomic nervous system. Understanding of the pathophysiology of CAN continues to evolve, with emerging evidence supporting a potential link between lipid metabolites, mitochondrial dysfunction and genetics. Recent advancements, such as streamlining CAN detection through wearable devices and monitoring of heart rate variability, present simplified and cost-effective approaches for early CAN detection. Further research on the optimal use of the extensive data provided by such devices is required. Despite the lack of specific pharmacological interventions targeting the underlying pathophysiology of autonomic neuropathy, several studies have suggested a favourable impact of newer glucose-lowering agents, such as sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, where there is a wealth of clinical trial data on the prevention of cardiovascular events. This review delves into recent developments in the area of CAN, with emphasis on practical guidance to recognise and manage this underdiagnosed condition, which significantly increases the risk of cardiovascular events and mortality in diabetes. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
- Endocrinology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
- Institute of Metabolism and Systems, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK.
- Department of Diabetes and Endocrinology, Birmingham Heartlands Hospital, Birmingham, UK.
- Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK. uazman.alam@liverpool.ac.uk.
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK. uazman.alam@liverpool.ac.uk.
Zitieren
APA
Eleftheriadou, A., Spallone, V., Tahrani, A. A., & Alam, U. (2024). Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management. Diabetologia, 67(12), 2611-2625. https://doi.org/10.1007/s00125-024-06242-0
Vancouver
Eleftheriadou A, Spallone V, Tahrani AA, Alam U. Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management. Diabetologia. 2024;67(12):2611-2625. doi:10.1007/s00125-024-06242-0
BibTeX
@article{Eleftheriadou2024,
author = {Eleftheriadou, Aikaterini and Spallone, Vincenza and Tahrani, Abd A and Alam, Uazman},
title = {Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management},
journal = {Diabetologia},
year = {2024},
volume = {67},
number = {12},
pages = {2611--2625},
doi = {10.1007/s00125-024-06242-0}
}
EUVIMED